NEWS CENTER

Keyuan Pharmaceutical Wins the "2025 Forbes China Industry Development Innovation Brand Award"!

Publish Time:

2025-03-23

On March 22, the "2025 Forbes China Industry Development Leader Selection" was held in Shanghai. Shandong Keyuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Keyuan Pharmaceutical"; stock code: 301281.SZ) was honored with the 2025 Forbes China Industry Development Innovation Brand Award, thanks to its outstanding innovation capabilities and significant industry influence. This prestigious award not only recognizes Keyuan Pharmaceutical's years of dedicated efforts in the chemical API and formulation sectors but also serves as a powerful testament to the company's ability to achieve transformative growth through innovation amid the ongoing global industrial restructuring.

"The 2025 Forbes China Industry Leader Innovators Selection," jointly launched by Frost & Sullivan, a globally renowned growth consulting firm, and Forbes China Group, aims to identify outstanding companies and individuals driving industry transformation through innovative spirit in key sectors such as new energy, AI technology, consumer goods, and biomedicine. This time, Keyuan Pharmaceutical has stood out, highlighting its exceptional position in the biomedicine sector.

Since its establishment in 2004, Keyuan Pharmaceutical has been dedicated to the research, development, production, and sales of chemical APIs and formulations. The company has built three core product lines—antidiabetic, cardiovascular, and anesthetic—making it a key enterprise in Shandong Province's chemical synthetic pharmaceutical sector. In April 2023, the company successfully listed on the ChiNext Board of the Shenzhen Stock Exchange, leveraging the capital market to further enhance its brand influence.

Currently, Keyuan Pharmaceutical is advancing its acquisition of Hongjitang, planning to purchase 99.42% of its equity by issuing shares and paying cash. If this acquisition succeeds, it will help Keyuan Pharmaceutical and Hongjitang leverage their respective strengths, fostering synergistic development between their chemical pharmaceutical and traditional Chinese medicine businesses.
Innovation is the core driving force behind Keway Pharmaceutical's development. The company continues to ramp up R&D investments, actively exploring cutting-edge technologies and continuously refining its innovation system. Recently, Keway Pharmaceutical was granted a utility model patent titled "A Raw Material Pre-processing and Drying Device for Metformin Hydrochloride Processing," marking the company's fourth patent authorization this year. These groundbreaking patent achievements provide robust support for enhancing product quality, boosting production efficiency, and optimizing cost control—empowering the company to maintain a competitive edge in today's fiercely contested market.

Looking ahead, Keyuan Pharmaceutical will take this award as an opportunity to continue upholding its innovation-driven philosophy, deepen R&D efforts, accelerate the integration with Hongjitang, steadily expand its product pipeline, and enhance its market share. Our goal is to deliver more high-quality, efficient medicines to patients, showcasing the strength of "China's Innovation" in the global pharmaceutical market—and ultimately contributing even more to the company's growth and the advancement of the industry.

Continuously advancing the internationalization strategy (Series 4) | Keyuan Pharmaceutical showcases at Japan International Pharmaceutical Raw Materials Exhibition and the European Cosmetics Ingredients Expo (Netherlands)!

Protecting Investors: Keyuan in Action | Stay Away from Illegal Stock Recommendations, Refuse Off-Exchange Margin Financing